Dipraglurant

Last updated
Dipraglurant
Dipraglurant.svg
Clinical data
Other namesADX-48621
ATC code
  • None
Identifiers
  • 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H12FN3
Molar mass 265.291 g·mol−1
3D model (JSmol)
  • c1ccnc(c1)C#CCCc2cn3cc(ccc3n2)F
  • InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2
  • Key:LZXMUJCJAWVHPZ-UHFFFAOYSA-N

Dipraglurant (INN; development code ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). [1] [2] [3] As of 2014, it is in phase II clinical trials for this indication. [1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia. [4]

Contents

See also

References

  1. 1 2 Martinez A, Gil C (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN   978-1-84973-617-6.
  2. ↑ Macor JE (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN   978-0-12-396492-2.
  3. ↑ Fox SH, Brotchie JM (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN   978-1-4471-6503-3.
  4. ↑ "Dipraglurant-ER for dystonia". Addex Therapeutics. Archived from the original on 2014-12-28. Retrieved 2014-12-28.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.